Health Care · Surgical & Medical Instruments & Apparatus

ANIK Anika Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 898437148 filings
Russell 2000

ANIK at a glance

Anika Therapeutics, Inc. (ANIK, SEC CIK 898437) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Anika Therapeutics, Inc. (ANIK) shares worth $106.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Fischetti Gary P on August 4, 2026 of 1,000 shares at $20.32 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$112.8M
−5.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$106.6M · +0 vs prior quarter
Latest 8-K
Nov 6, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Carried-forward business risk: disclosed risks could materially affect future results
  • Carried-forward uncertainty risk: unknown or currently immaterial risks could materially harm operations

Management Discussion & Analysis

  • Revenue $30.6M, up 10% YoY from $27.8M, driven by Commercial Channel growth
  • Gross margin 62% vs 56% YoY, with net loss $0.3M vs $3.2M
  • Best segment Commercial Channel revenue $14.0M, up 17%; Integrity sales supported regenerative growth
  • Cash $45.0M vs $57.5M at December 31, 2025; operating cash flow $2.8M vs $6.6M
  • Hyalofast PMA not approvable; Cingal NDA submission targeted by December 31, 2027

AI summary of the ANIK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $30.6M, up 10%, with Commercial Channel growth 17% and OEM growth 5%
  • Gross margin expanded to 62% from 56%, while adjusted EBITDA increased to $5.1M from $0.9M
Filed Jul 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1 contains financial results

Item EX-99.1: Item EX-99.1

  • Q2 revenue $32.6M, up 16%, with Commercial Channel revenue up 17% to record $13.9M
  • Gross margin expanded to 65%, driving $3.3M GAAP net income and $7.1M adjusted EBITDA
Filed Jul 14, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $50.0M senior revolving credit facility extended through July 10, 2031
  • Potential $50.0M expansion, bringing maximum commitments to $100.0M subject to lender approval

AI summaries of ANIK 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ANIK

Don't miss the next ANIK filing

  • Alerts as it files. A push when ANIK files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ANIK, by share count.
  • Ask anything. An AI agent that reads every ANIK filing and answers with sources.

ANIK alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Fischetti Gary PBuyAug 4, 2026$20.32
Fischetti Gary PBuyAug 3, 2026$20.75
Fischetti Gary PAJun 18, 2026-
CONLEY SHERYL LAJun 18, 2026-
HENNEMAN JOHN B IIIAJun 18, 2026-
Richard StephenAJun 18, 2026-
Capper Joseph HAJun 18, 2026-
Griffin Stephen D.FJun 3, 2026$14.41

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$119.9M$112.8M
Gross Profit-$76.0M$63.8M
Operating Income--$5.1M-$11.1M
Net Income--$56.4M-$10.9M
Gross Margin-63.4%56.6%
Op. Margin--4.3%-9.8%
Net Margin--47.0%-9.6%
Balance Sheet
Total Assets$270.6M$202.7M$190.3M
Equity$212.3M$154.0M$143.5M
ROE--36.6%-7.6%
Per Share
EPS-$-3.83$-0.76
Cash Flow
Operating CF-$5.4M$11.2M
CapEx-$7.7M$6.8M

Source: XBRL data in Anika Therapeutics, Inc. (ANIK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ANIK share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ANIK shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$106.6M
Q2 202624$82.6M
Q1 202623$84.3M
Q4 202522$55.5M
Q3 202522$48.8M
Q2 202523$48.5M
Q1 202521$46.6M
Q4 202417$46.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 176 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ANIK filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 6, 2026Analysis-
4Aug 5, 2026--
8-KJul 29, 2026Analysis-
10-QJul 29, 2026Analysis
8-KJul 14, 2026Analysis-
4Jun 23, 2026--
4Jun 23, 2026--
8-KJun 23, 2026Analysis-
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 23, 2026--
4Jun 5, 2026-
4May 4, 2026--
4Apr 30, 2026--
10-QApr 30, 2026Analysis
8-KApr 29, 2026Analysis-
SC 13GApr 29, 2026-
4Mar 23, 2026--
4Mar 17, 2026--
4Mar 17, 2026--
4Mar 17, 2026--
4Mar 11, 2026--
4Mar 11, 2026--
4Mar 11, 2026--

Related Health Care companies

All Health Care →

ANIK SEC filings: frequently asked questions

Which institutions hold ANIK stock?

As of September 30, 2026, the largest Anika Therapeutics, Inc. (ANIK) holders among the 13F filers tracked by SignalX were BlackRock ($27.7 million), Morgan Stanley ($12.3 million), Vanguard Capital Management LLC ($11.1 million), Dimensional Fund Advisors ($9.1 million), Renaissance Technologies LLC ($9.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ANIK's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Anika Therapeutics, Inc. (ANIK) reported revenue of $112.8 million (down 5.9% from FY2024) and a net loss of $10.9 million. Diluted EPS was -$0.76. The figures come from the XBRL data in the 10-K.

What did ANIK report in its latest 8-K?

Anika Therapeutics, Inc. (ANIK) filed an 8-K on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest ANIK SEC filings?

Anika Therapeutics, Inc. (ANIK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on August 5, 2026.

What is ANIK's SEC CIK number?

Anika Therapeutics, Inc. (ANIK)'s SEC Central Index Key (CIK) is 898437. EDGAR lists every ANIK filing under that number.

Ask anything about ANIK

The research agent reads ANIK's filings, financials, insider trades and 13F holders, then answers with sources.